| Robert D. Hillstead, Inc | |
|
840 Pinnacle Ct Ste 10a, Mesquite, NV 89027-3304 | |
| (702) 346-1994 | |
| (702) 346-2056 |
| Full Name | Robert D. Hillstead, Inc |
|---|---|
| Type | Facility |
| Speciality | Optometrist |
| Location | 840 Pinnacle Ct Ste 10a, Mesquite, Nevada |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073702841 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 261 (Nevada) | Primary |
| Provider Name | Robert D Hillstead |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1497811467 PECOS PAC ID: 6800985722 Enrollment ID: I20071130000013 |
News Archive
Amgen today announced results from the Phase 2 PEAK study that reinforce the improved overall survival (OS) benefit of panitumumab (Vectibix®) when used in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, compared to bevacizumab (Avastin) plus FOLFOX as first-line treatment in patients with wild-type RAS metastatic colorectal cancer (mCRC).
US scientists have developed a prototype breast cancer vaccine that has shown promising results in very early laboratory tests on mice. The vaccine contains a protein called alpha-lactalbumin, which is found in large quantities in the majority of breast cancers.
A new technology assessment from the American Society of Clinical Oncology states that the use of chemotherapy sensitivity and resistance assays (CSRAs) to select chemotherapeutic agents for cancer patients should not be undertaken outside of the clinical trial setting.
Researchers at The Feinstein Institute for Medical Research have discovered that inflammation could be treated by targeting a molecule called the double-stranded RNA dependent protein kinase (PKR). These findings are published in the July issue of Nature.
BGI has published a study tracking the clinical performance of its whole genome sequencing-based non-invasive prenatal test (the NIFTY test) in nearly 147,000 pregnancies, the largest such study to date. The results showed high sensitivity and specificity and no significant difference between high-risk and low-risk pregnant women.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Robert D. Hillstead, Inc 840 Pinnacle Ct Ste 10a, Mesquite, NV 89027-3304 Ph: (702) 346-1994 | Robert D. Hillstead, Inc 840 Pinnacle Ct Ste 10a, Mesquite, NV 89027-3304 Ph: (702) 346-1994 |
News Archive
Amgen today announced results from the Phase 2 PEAK study that reinforce the improved overall survival (OS) benefit of panitumumab (Vectibix®) when used in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, compared to bevacizumab (Avastin) plus FOLFOX as first-line treatment in patients with wild-type RAS metastatic colorectal cancer (mCRC).
US scientists have developed a prototype breast cancer vaccine that has shown promising results in very early laboratory tests on mice. The vaccine contains a protein called alpha-lactalbumin, which is found in large quantities in the majority of breast cancers.
A new technology assessment from the American Society of Clinical Oncology states that the use of chemotherapy sensitivity and resistance assays (CSRAs) to select chemotherapeutic agents for cancer patients should not be undertaken outside of the clinical trial setting.
Researchers at The Feinstein Institute for Medical Research have discovered that inflammation could be treated by targeting a molecule called the double-stranded RNA dependent protein kinase (PKR). These findings are published in the July issue of Nature.
BGI has published a study tracking the clinical performance of its whole genome sequencing-based non-invasive prenatal test (the NIFTY test) in nearly 147,000 pregnancies, the largest such study to date. The results showed high sensitivity and specificity and no significant difference between high-risk and low-risk pregnant women.
› Verified 7 days ago
Dr. Scott Kirk Brotherson, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 61 N Willow St, Suite 2, Mesquite, NV 89027 Phone: 702-346-3031 | |
Brett P Richardson Od Pllc Optometrist Medicare: Medicare Enrolled Practice Location: 1120 W Pioneer Blvd, Mesquite, NV 89027 Phone: 360-991-9548 | |
Dr. Robert D. Hillstead, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 840 Pinnacle Ct Ste 10a, Mesquite, NV 89027 Phone: 702-346-1994 Fax: 702-346-2056 | |
Vision Consultants Optometrist Medicare: Not Enrolled in Medicare Practice Location: 272 W Pioneer Blvd, Mesquite, NV 89027 Phone: 775-375-8869 | |
Brett Richardson, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1120 W Pioneer Blvd, Mesquite, NV 89027 Phone: 360-991-9548 | |
Scott K Brotherson O.d. Optometrist Medicare: Medicare Enrolled Practice Location: 61 N Willow St, Suite 2, Mesquite, NV 89027 Phone: 702-346-3031 Fax: 702-346-0920 |